Barricaid Anular Closure

Reherniation Reduction Device

FDA Premarket Approval P160050 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval of two protocols for the post-approval study (pas) protocol.

DeviceBarricaid Anular Closure
Classification NameReherniation Reduction Device
Generic NameReherniation Reduction Device
ApplicantINTRINSIC THERAPEUTICS
Date Received2019-03-08
Decision Date2019-05-07
PMAP160050
SupplementS001
Product CodeQES
Advisory CommitteeOrthopedic
Supplement TypeNormal 180 Day Track No User Fee
Supplement ReasonPostapproval Study Protocol - Ode/oir
Expedited ReviewNo
Combination Product No
Applicant Address INTRINSIC THERAPEUTICS 30 Commerce Way woburn, MA 01801

Supplemental Filings

Supplement NumberDateSupplement Type
P160050Original Filing
S006 2020-04-22 Normal 180 Day Track No User Fee
S005 2020-04-16 Normal 180 Day Track No User Fee
S004
S003 2019-03-19 Real-time Process
S002 2019-03-11 135 Review Track For 30-day Notice
S001 2019-03-08 Normal 180 Day Track No User Fee

NIH GUDID Devices

Device IDPMASupp
M906BARA810MM0 P160050 000
M906BARA88MM0 P160050 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.